AlphaCore Capital LLC boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 166.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,850 shares of the company’s stock after buying an additional 1,779 shares during the quarter. AlphaCore Capital LLC’s holdings in Elevance Health were worth $999,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of ELV. Physician Wealth Advisors Inc. increased its position in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the period. Activest Wealth Management boosted its holdings in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the period. Rossby Financial LCC grew its stake in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares in the last quarter. ORG Partners LLC grew its stake in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Elevance Health during the 4th quarter worth about $38,000. Institutional investors and hedge funds own 89.24% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on ELV shares. Jefferies Financial Group decreased their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Truist Financial cut their target price on shares of Elevance Health from $390.00 to $375.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Guggenheim raised their target price on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Barclays lifted their price target on shares of Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. Finally, Bank of America upgraded shares of Elevance Health from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $405.00 to $435.00 in a report on Wednesday, April 29th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.
Elevance Health Price Performance
ELV stock opened at $393.35 on Tuesday. The business has a 50 day moving average price of $325.02 and a 200 day moving average price of $334.34. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $85.42 billion, a price-to-earnings ratio of 16.73, a PEG ratio of 2.23 and a beta of 0.66. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $412.96.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same period in the prior year, the firm posted $11.97 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts anticipate that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.
Elevance Health Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.
About Elevance Health
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
- Five stocks we like better than Elevance Health
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
